

DOCKET NO. 7732-020-27 DIV



RECEIVED

MAY 15 2002

TECH CENTER 1600/2900

5-16-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: MICHAEL CLIMO, ET AL. ART UNIT: 1631

SERIAL NO.: 09/665,077

EXAMINER: Michael L. Borin

FILING DATE: SEPTEMBER 19, 2000

FOR: COMPOSITIONS AND METHODS FOR TREATMENT OF
STAPHYLOCOCCAL INFECTION WHILE SUPPRESSING
FORMATION OF ANTIBIOTIC-RESISTANT STRAINS

RESPONSE TO RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

SIR:

Responsive to the Restriction Requirement dated March 13, 2002, Applicants elect, albeit with traverse, Group II, Claims 18-22, 24-28, drawn to methods of treating staphylococcal infections, for further prosecution at this time.

IN THE CLAIMS

Please amend Claim 18 as indicated below.

9 18. (Amended) A method of enhancing the effectiveness of lysostaphin as a bacteriocin in a method of treatment by suppressing formation of staphylococcal strains resistant thereto, comprising combining an amount of lysostaphin independently effective in therapeutically treating a staphylococcal infection in a mammal with an amount of a cell-wall active antibiotic sufficient to treat, independently, a staphylococcal infection in a mammal, wherein both the lysostaphin and the cell-wall active antibiotic are present in amounts which, when co-administered, suppress the formation of staphylococcal strains resistant to the lysostaphin, the cell-wall active antibiotic and combinations of lysostaphin and the cell-wall active antibiotic.